Jerome Benedict Durso

Insider · President and CEO · ALT

Jerome Benedict Durso files insider transactions with the SEC as a president and ceo of Altimmune (ALT). We hold 3 disclosed purchases and sales filed since 27 February 2017, 1 of them in the last 90 days.

Files forALT
Disclosed buys and sells3 in all, 1 in the last 90 days
Last disclosure13 August 2026

Positions held

2 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 24 February 2025 — 13 August 2026President and CEO · Altimmune (ALT)9 Form 4 lines · source: SEC Form 4
Filed 23 February 2017 — 8 November 2023CEO · Intercept Pharmaceuticals (ICPT)56 Form 4 lines · source: SEC Form 4

Everything they disclosed

65 entries, newest first — one per disclosure report, one per Form 4 line

▲ bought on the open market 15,000 shares of AltimmuneSEC Form 413 August 2026Common Stock, par value $0.0001 · traded 13 August 2026 · filed 13 August 2026
▲ bought on the open market 15,000 shares of AltimmuneSEC Form 41 April 2026Common Stock, par value $0.0001 · traded 1 April 2026 · filed 1 April 2026
▲ bought on the open market 20,000 shares of AltimmuneSEC Form 49 March 2026Common Stock, par value $0.0001 · traded 6 March 2026 · filed 9 March 2026
▲ bought on the open market 20,000 shares of AltimmuneSEC Form 49 March 2026Common Stock, par value $0.0001 · traded 6 March 2026 · filed 9 March 2026
▲ bought on the open market 12,500 shares of AltimmuneSEC Form 422 December 2025Common Stock, par value $0.0001 · traded 22 December 2025 · filed 22 December 2025
was granted 1,824,400 shares of Altimmune (a derivative holding)SEC Form 41 December 2025Stock Options (option to buy) · traded 1 December 2025 · filed 1 December 2025
was granted 633,700 shares of Altimmune (a derivative holding)SEC Form 41 December 2025Restricted Stock Units · traded 1 December 2025 · filed 1 December 2025
was granted 48,800 shares of Altimmune (a derivative holding)SEC Form 429 September 2025Stock Options (option to buy) · traded 25 September 2025 · filed 29 September 2025
was granted 69,800 shares of Altimmune (a derivative holding)SEC Form 425 February 2025Stock Options (option to buy) · traded 24 February 2025 · filed 25 February 2025
returned to the issuer 60,900 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 413 November 2023Option to Purchase Common Stock · traded 8 November 2023 · filed 13 November 2023
returned to the issuer 82,700 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 413 November 2023Option to Purchase Common Stock · traded 8 November 2023 · filed 13 November 2023
returned to the issuer 3,419 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 413 November 2023Option to Purchase Common Stock · traded 8 November 2023 · filed 13 November 2023
returned to the issuer 16,581 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 413 November 2023Option to Purchase Common Stock · traded 8 November 2023 · filed 13 November 2023
returned to the issuer 71 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 413 November 2023Option to Purchase Common Stock · traded 8 November 2023 · filed 13 November 2023
returned to the issuer 20,629 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 413 November 2023Option to Purchase Common Stock · traded 8 November 2023 · filed 13 November 2023
returned to the issuer 896 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 413 November 2023Option to Purchase Common Stock · traded 8 November 2023 · filed 13 November 2023
returned to the issuer 14,304 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 413 November 2023Option to Purchase Common Stock · traded 8 November 2023 · filed 13 November 2023
returned to the issuer 17,400 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 413 November 2023Option to Purchase Common Stock · traded 8 November 2023 · filed 13 November 2023
returned to the issuer 72,000 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 413 November 2023Option to Purchase Common Stock · traded 8 November 2023 · filed 13 November 2023
disposed of in a tender offer 51,815 shares of Intercept PharmaceuticalsSEC Form 413 November 2023Common Stock · traded 8 November 2023 · filed 13 November 2023
returned to the issuer 102,825 shares of Intercept PharmaceuticalsSEC Form 413 November 2023Common Stock · traded 8 November 2023 · filed 13 November 2023
was granted 82,700 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 431 January 2023Option to Purchase Common Stock · traded 27 January 2023 · filed 31 January 2023
was granted 50,400 shares of Intercept PharmaceuticalsSEC Form 431 January 2023Common Stock · traded 27 January 2023 · filed 31 January 2023
had shares withheld for tax on 7,083 shares of Intercept PharmaceuticalsSEC Form 43 January 2023Common Stock · traded 31 December 2022 · filed 3 January 2023
was granted 60,900 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 431 January 2022Option to Purchase Common Stock · traded 27 January 2022 · filed 31 January 2022
was granted 35,700 shares of Intercept PharmaceuticalsSEC Form 431 January 2022Common Stock · traded 27 January 2022 · filed 31 January 2022
had shares withheld for tax on 5,607 shares of Intercept PharmaceuticalsSEC Form 44 January 2022Common Stock · traded 31 December 2021 · filed 4 January 2022
had shares withheld for tax on 334 shares of Intercept PharmaceuticalsSEC Form 44 January 2022Common Stock · traded 1 January 2022 · filed 4 January 2022
had shares withheld for tax on 289 shares of Intercept PharmaceuticalsSEC Form 45 October 2021Common Stock · traded 1 October 2021 · filed 5 October 2021
had shares withheld for tax on 289 shares of Intercept PharmaceuticalsSEC Form 42 July 2021Common Stock · traded 1 July 2021 · filed 2 July 2021
had shares withheld for tax on 289 shares of Intercept PharmaceuticalsSEC Form 45 April 2021Common Stock · traded 1 April 2021 · filed 5 April 2021
had shares withheld for tax on 319 shares of Intercept PharmaceuticalsSEC Form 425 February 2021Common Stock · traded 23 February 2021 · filed 25 February 2021
was granted 46,000 shares of Intercept PharmaceuticalsSEC Form 426 January 2021Common Stock · traded 22 January 2021 · filed 26 January 2021
was granted 72,000 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 426 January 2021Option to Purchase Common Stock · traded 22 January 2021 · filed 26 January 2021
had shares withheld for tax on 1,700 shares of Intercept PharmaceuticalsSEC Form 45 January 2021Common Stock · traded 31 December 2020 · filed 5 January 2021
had shares withheld for tax on 334 shares of Intercept PharmaceuticalsSEC Form 45 January 2021Common Stock · traded 1 January 2021 · filed 5 January 2021
had shares withheld for tax on 319 shares of Intercept PharmaceuticalsSEC Form 425 November 2020Common Stock · traded 23 November 2020 · filed 25 November 2020
had shares withheld for tax on 289 shares of Intercept PharmaceuticalsSEC Form 45 October 2020Common Stock · traded 1 October 2020 · filed 5 October 2020
had shares withheld for tax on 319 shares of Intercept PharmaceuticalsSEC Form 425 August 2020Common Stock · traded 23 August 2020 · filed 25 August 2020
had shares withheld for tax on 289 shares of Intercept PharmaceuticalsSEC Form 46 July 2020Common Stock · traded 1 July 2020 · filed 6 July 2020
had shares withheld for tax on 319 shares of Intercept PharmaceuticalsSEC Form 427 May 2020Common Stock · traded 23 May 2020 · filed 27 May 2020
had shares withheld for tax on 289 shares of Intercept PharmaceuticalsSEC Form 43 April 2020Common Stock · traded 1 April 2020 · filed 3 April 2020
had shares withheld for tax on 319 shares of Intercept PharmaceuticalsSEC Form 424 February 2020Common Stock · traded 23 February 2020 · filed 24 February 2020
was granted 17,400 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 427 January 2020Option to Purchase Common Stock · traded 23 January 2020 · filed 27 January 2020
was granted 10,600 shares of Intercept PharmaceuticalsSEC Form 427 January 2020Common Stock · traded 23 January 2020 · filed 27 January 2020
had shares withheld for tax on 1,151 shares of Intercept PharmaceuticalsSEC Form 43 January 2020Common Stock · traded 31 December 2019 · filed 3 January 2020
had shares withheld for tax on 334 shares of Intercept PharmaceuticalsSEC Form 43 January 2020Common Stock · traded 1 January 2020 · filed 3 January 2020
had shares withheld for tax on 460 shares of Intercept PharmaceuticalsSEC Form 426 November 2019Common Stock · traded 23 November 2019 · filed 26 November 2019
had shares withheld for tax on 417 shares of Intercept PharmaceuticalsSEC Form 43 October 2019Common Stock · traded 1 October 2019 · filed 3 October 2019
had shares withheld for tax on 319 shares of Intercept PharmaceuticalsSEC Form 427 August 2019Common Stock · traded 23 August 2019 · filed 27 August 2019
had shares withheld for tax on 289 shares of Intercept PharmaceuticalsSEC Form 43 July 2019Common Stock · traded 1 July 2019 · filed 3 July 2019
had shares withheld for tax on 460 shares of Intercept PharmaceuticalsSEC Form 428 May 2019Common Stock · traded 23 May 2019 · filed 28 May 2019
had shares withheld for tax on 289 shares of Intercept PharmaceuticalsSEC Form 43 April 2019Common Stock · traded 1 April 2019 · filed 3 April 2019
had shares withheld for tax on 319 shares of Intercept PharmaceuticalsSEC Form 426 February 2019Common Stock · traded 23 February 2019 · filed 26 February 2019
was granted 15,200 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 418 January 2019Option to Purchase Common Stock · traded 16 January 2019 · filed 18 January 2019
was granted 9,400 shares of Intercept PharmaceuticalsSEC Form 418 January 2019Common Stock · traded 16 January 2019 · filed 18 January 2019
had shares withheld for tax on 1,219 shares of Intercept PharmaceuticalsSEC Form 43 January 2019Common Stock · traded 1 January 2019 · filed 3 January 2019
had shares withheld for tax on 460 shares of Intercept PharmaceuticalsSEC Form 427 November 2018Common Stock · traded 23 November 2018 · filed 27 November 2018
had shares withheld for tax on 1,318 shares of Intercept PharmaceuticalsSEC Form 43 October 2018Common Stock · traded 23 February 2018 · filed 3 October 2018
had shares withheld for tax on 319 shares of Intercept PharmaceuticalsSEC Form 43 October 2018Common Stock · traded 23 May 2018 · filed 3 October 2018
had shares withheld for tax on 319 shares of Intercept PharmaceuticalsSEC Form 43 October 2018Common Stock · traded 23 August 2018 · filed 3 October 2018
was granted 20,700 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 422 February 2018Option to Purchase Common Stock · traded 5 February 2018 · filed 22 February 2018
was granted 13,600 shares of Intercept PharmaceuticalsSEC Form 422 February 2018Common Stock · traded 5 February 2018 · filed 22 February 2018
was granted 15,000 shares of Intercept PharmaceuticalsSEC Form 427 February 2017Common Stock · traded 23 February 2017 · filed 27 February 2017
was granted 20,000 shares of Intercept Pharmaceuticals (a derivative holding)SEC Form 427 February 2017Option to Purchase Common Stock · traded 23 February 2017 · filed 27 February 2017

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.